nodes	percent_of_prediction	percent_of_DWPC	metapath
Pranlukast—MUC2—forebrain—attention deficit hyperactivity disorder	0.065	0.16	CbGeAlD
Pranlukast—NFKB1—forebrain—attention deficit hyperactivity disorder	0.0371	0.0912	CbGeAlD
Pranlukast—MUC2—nervous system—attention deficit hyperactivity disorder	0.0353	0.0868	CbGeAlD
Pranlukast—MUC2—central nervous system—attention deficit hyperactivity disorder	0.034	0.0836	CbGeAlD
Pranlukast—MUC2—cerebellum—attention deficit hyperactivity disorder	0.0332	0.0817	CbGeAlD
Pranlukast—NFKB1—cardiovascular system—attention deficit hyperactivity disorder	0.0314	0.0771	CbGeAlD
Pranlukast—MUC2—brain—attention deficit hyperactivity disorder	0.027	0.0663	CbGeAlD
Pranlukast—NFKB1—nervous system—attention deficit hyperactivity disorder	0.0201	0.0495	CbGeAlD
Pranlukast—CYSLTR1—nervous system—attention deficit hyperactivity disorder	0.0198	0.0486	CbGeAlD
Pranlukast—NFKB1—central nervous system—attention deficit hyperactivity disorder	0.0194	0.0476	CbGeAlD
Pranlukast—TNF—Matrix Metalloproteinases—MMP16—attention deficit hyperactivity disorder	0.0193	0.0325	CbGpPWpGaD
Pranlukast—CYSLTR1—central nervous system—attention deficit hyperactivity disorder	0.019	0.0468	CbGeAlD
Pranlukast—NFKB1—cerebellum—attention deficit hyperactivity disorder	0.0189	0.0466	CbGeAlD
Pranlukast—NFKB1—brain—attention deficit hyperactivity disorder	0.0154	0.0378	CbGeAlD
Pranlukast—CYSLTR1—brain—attention deficit hyperactivity disorder	0.0151	0.0372	CbGeAlD
Pranlukast—NFKB1—Cytosolic sensors of pathogen-associated DNA—MB21D1—attention deficit hyperactivity disorder	0.0151	0.0255	CbGpPWpGaD
Pranlukast—TNF—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.0118	0.0199	CbGpPWpGaD
Pranlukast—IL5—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.0118	0.0198	CbGpPWpGaD
Pranlukast—TNF—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.0116	0.0196	CbGpPWpGaD
Pranlukast—NFKB1—Cytosolic sensors of pathogen-associated DNA—POLR3A—attention deficit hyperactivity disorder	0.0111	0.0187	CbGpPWpGaD
Pranlukast—NFKB1—p75 NTR receptor-mediated signalling—RTN4—attention deficit hyperactivity disorder	0.0102	0.0171	CbGpPWpGaD
Pranlukast—NFKB1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0101	0.017	CbGpPWpGaD
Pranlukast—NFKB1—Oxidative Stress—MAOA—attention deficit hyperactivity disorder	0.00981	0.0165	CbGpPWpGaD
Pranlukast—TNF—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.00943	0.0159	CbGpPWpGaD
Pranlukast—TNF—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00841	0.0142	CbGpPWpGaD
Pranlukast—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.0082	0.0202	CbGeAlD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00746	0.0126	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00731	0.0123	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00726	0.0122	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00639	0.0108	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00626	0.0106	CbGpPWpGaD
Pranlukast—IL5—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00618	0.0104	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00606	0.0102	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00578	0.00975	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00571	0.00963	CbGpPWpGaD
Pranlukast—IL5—AP-1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00529	0.00892	CbGpPWpGaD
Pranlukast—TNF—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00524	0.00883	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00519	0.00875	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00507	0.00854	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00487	0.0082	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00477	0.00804	CbGpPWpGaD
Pranlukast—IL5—Regulation of nuclear SMAD2/3 signaling—EP300—attention deficit hyperactivity disorder	0.00471	0.00794	CbGpPWpGaD
Pranlukast—IL5—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.00466	0.00786	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00443	0.00746	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00436	0.00735	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00434	0.00732	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00412	0.00694	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0041	0.00691	CbGpPWpGaD
Pranlukast—NFKB1—Initiation of transcription and translation elongation at the HIV-1 LTR—EP300—attention deficit hyperactivity disorder	0.00402	0.00678	CbGpPWpGaD
Pranlukast—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00401	0.00987	CbGeAlD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00399	0.00672	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00392	0.00661	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00387	0.00652	CbGpPWpGaD
Pranlukast—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00387	0.0095	CbGeAlD
Pranlukast—IL5—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00383	0.00646	CbGpPWpGaD
Pranlukast—IL5—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00382	0.00644	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00379	0.0064	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00375	0.00633	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00375	0.00632	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00374	0.0063	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00372	0.00628	CbGpPWpGaD
Pranlukast—IL5—Immune System—STUB1—attention deficit hyperactivity disorder	0.0037	0.00624	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00361	0.00608	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00353	0.00595	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00349	0.00588	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00349	0.00588	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00348	0.00587	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00342	0.00576	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00341	0.00575	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00336	0.00566	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00332	0.0056	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00332	0.00559	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00331	0.00557	CbGpPWpGaD
Pranlukast—CYSLTR1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00327	0.00551	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00319	0.00537	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00309	0.00521	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00307	0.00517	CbGpPWpGaD
Pranlukast—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00306	0.00516	CbGpPWpGaD
Pranlukast—NFKB1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00301	0.00507	CbGpPWpGaD
Pranlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00292	0.00493	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00289	0.00487	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00286	0.00482	CbGpPWpGaD
Pranlukast—IL5—Immune System—POLR3A—attention deficit hyperactivity disorder	0.0028	0.00473	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00275	0.00464	CbGpPWpGaD
Pranlukast—NFKB1—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.0027	0.00455	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00269	0.00454	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00269	0.00453	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00267	0.00449	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00266	0.00448	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00266	0.00448	CbGpPWpGaD
Pranlukast—NFKB1—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00265	0.00446	CbGpPWpGaD
Pranlukast—NFKB1—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00265	0.00446	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00262	0.00442	CbGpPWpGaD
Pranlukast—ABCC2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00261	0.0044	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.0026	0.00439	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.0026	0.00438	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00256	0.00431	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00253	0.00427	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00253	0.00426	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00253	0.00426	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0025	0.00421	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00248	0.00418	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00246	0.00415	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00245	0.00413	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00241	0.00406	CbGpPWpGaD
Pranlukast—NFKB1—Notch Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.0024	0.00405	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00239	0.00403	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00239	0.00402	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00236	0.00398	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00235	0.00397	CbGpPWpGaD
Pranlukast—ABCC2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00233	0.00392	CbGpPWpGaD
Pranlukast—TNF—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00229	0.00387	CbGpPWpGaD
Pranlukast—TNF—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00229	0.00387	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00227	0.00383	CbGpPWpGaD
Pranlukast—NFKB1—Cytosolic sensors of pathogen-associated DNA—EP300—attention deficit hyperactivity disorder	0.00225	0.0038	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.0022	0.00371	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00216	0.00365	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00215	0.00363	CbGpPWpGaD
Pranlukast—NFKB1—Signaling events mediated by HDAC Class I—EP300—attention deficit hyperactivity disorder	0.00215	0.00363	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00214	0.00361	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00214	0.0036	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00211	0.00356	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00207	0.00348	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00206	0.00347	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00205	0.00345	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00204	0.00344	CbGpPWpGaD
Pranlukast—TNF—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00202	0.0034	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00201	0.0034	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00201	0.00339	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.002	0.00337	CbGpPWpGaD
Pranlukast—NFKB1—Transcriptional regulation of white adipocyte differentiation—EP300—attention deficit hyperactivity disorder	0.00199	0.00336	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00199	0.00335	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00198	0.00333	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00196	0.0033	CbGpPWpGaD
Pranlukast—NFKB1—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—attention deficit hyperactivity disorder	0.00193	0.00326	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00193	0.00325	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00192	0.00324	CbGpPWpGaD
Pranlukast—NFKB1—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.0019	0.00319	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00187	0.00316	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00187	0.00315	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00186	0.00314	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00185	0.00312	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00183	0.00308	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00182	0.00306	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00181	0.00304	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00173	0.00292	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00172	0.0029	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0017	0.00286	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00168	0.00284	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00165	0.00278	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00164	0.00276	CbGpPWpGaD
Pranlukast—TNF—Signaling events mediated by HDAC Class I—EP300—attention deficit hyperactivity disorder	0.00164	0.00276	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00163	0.00275	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00163	0.00275	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00159	0.00267	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00155	0.00262	CbGpPWpGaD
Pranlukast—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—attention deficit hyperactivity disorder	0.00152	0.00256	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00152	0.00256	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—STUB1—attention deficit hyperactivity disorder	0.0015	0.00254	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00148	0.0025	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00148	0.00249	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00147	0.00248	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00145	0.00244	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00144	0.00244	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00143	0.00241	CbGpPWpGaD
Pranlukast—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00143	0.0024	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00142	0.00239	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.0014	0.00235	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00138	0.00232	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00133	0.00225	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00133	0.00224	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00132	0.00223	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00131	0.00221	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.0013	0.00219	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.0013	0.00218	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00125	0.0021	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00122	0.00206	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00121	0.00204	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00121	0.00204	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00118	0.00199	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00116	0.00196	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00114	0.00192	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00113	0.00191	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00113	0.00191	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.0011	0.00185	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—EP300—attention deficit hyperactivity disorder	0.00109	0.00183	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00108	0.00182	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00107	0.0018	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.001	0.00169	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000994	0.00168	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000972	0.00164	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000963	0.00162	CbGpPWpGaD
Pranlukast—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00094	0.00158	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000931	0.00157	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000876	0.00148	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000863	0.00145	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000845	0.00143	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000835	0.00141	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000818	0.00138	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000814	0.00137	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000803	0.00135	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000789	0.00133	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000775	0.00131	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000765	0.00129	CbGpPWpGaD
Pranlukast—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000762	0.00129	CbGpPWpGaD
Pranlukast—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000757	0.00128	CbGpPWpGaD
Pranlukast—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000752	0.00127	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000745	0.00126	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000744	0.00125	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000734	0.00124	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000713	0.0012	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000696	0.00117	CbGpPWpGaD
Pranlukast—IL5—Immune System—EP300—attention deficit hyperactivity disorder	0.00057	0.000961	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000567	0.000956	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000503	0.000848	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000499	0.000842	CbGpPWpGaD
Pranlukast—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000499	0.000842	CbGpPWpGaD
Pranlukast—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000496	0.000836	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000496	0.000836	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000461	0.000777	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.00045	0.000759	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000446	0.000753	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000439	0.00074	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000433	0.000731	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000404	0.000681	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000398	0.000671	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000369	0.000622	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000343	0.000579	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000312	0.000526	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000283	0.000477	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000265	0.000446	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—EP300—attention deficit hyperactivity disorder	0.000232	0.000391	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000215	0.000363	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000215	0.000363	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000212	0.000357	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000206	0.000347	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000197	0.000332	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000172	0.00029	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000164	0.000276	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00015	0.000253	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000142	0.000239	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000142	0.000239	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00014	0.000235	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.00013	0.00022	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00013	0.000219	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000129	0.000218	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000126	0.000212	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000113	0.000191	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000108	0.000182	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	8.6e-05	0.000145	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	8.54e-05	0.000144	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	5.59e-05	9.43e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.69e-05	6.22e-05	CbGpPWpGaD
